Cavernous sinus thrombosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
YazanDaaboul (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapies for cavernous sinus thrombosis include antithombotic agents, antibiotics, and drugs such as [[mannitol]], [[steroids]] and [[acetazolamide]] to decrease the [[intracranial pressure]]. Empiric antimicrobial therapy for septic thrombosis of cavernous or dural venous sinus includes [[metronidazole]] plus either [[nafcillin]] or [[oxacillin]] with either [[ceftriaxone]] or [[cefotaxime]]. Generally, the preferred empiric regimen for the treatment of cavernous sinus thrombosis is ([[Vancomycin]] 30–45 mg/kg IV q8–12h for 3-4 weeks {{or}} [[Nafcillin]] 2 g IV q4h for 3-4 weeks {{or}} [[Oxacillin]] 2 g IV q4h for 3-4 weeks) {{and}} ([[Ceftriaxone]] 2 g IV q12h for 3-4 weeks {{or}} [[Cefotaxime]] 8–12 g/day IV q4–6h for 3-4 weeks) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h for 3-4 weeks. If the risk of [[MRSA]] is high, vancomycin should be used instead of either nafcillin or oxacillin. Other pharmacologic therapies include antithrombotic agents (usually LMWH) to prevent clot formation, steroid therapy (e.g. [[Dexamethasone]] 10 mg q6h) for symptomatic relief, and [[mannitol]] and [[acetazolamide]] to reduce the elevated intracranial pressure. Antiepileptic therapy should be administered only if patients develop seizures. | Cavernous sinus thrombosis is a medical emergency. Pharmacologic medical therapies for cavernous sinus thrombosis include antithombotic agents, antibiotics, and drugs such as [[mannitol]], [[steroids]] and [[acetazolamide]] to decrease the [[intracranial pressure]]. Empiric antimicrobial therapy for septic thrombosis of cavernous or dural venous sinus includes [[metronidazole]] plus either [[nafcillin]] or [[oxacillin]] with either [[ceftriaxone]] or [[cefotaxime]]. Generally, the preferred empiric regimen for the treatment of cavernous sinus thrombosis is ([[Vancomycin]] 30–45 mg/kg IV q8–12h for 3-4 weeks {{or}} [[Nafcillin]] 2 g IV q4h for 3-4 weeks {{or}} [[Oxacillin]] 2 g IV q4h for 3-4 weeks) {{and}} ([[Ceftriaxone]] 2 g IV q12h for 3-4 weeks {{or}} [[Cefotaxime]] 8–12 g/day IV q4–6h for 3-4 weeks) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h for 3-4 weeks. If the risk of [[MRSA]] is high, vancomycin should be used instead of either nafcillin or oxacillin. Other pharmacologic therapies include antithrombotic agents (usually LMWH) to prevent clot formation, steroid therapy (e.g. [[Dexamethasone]] 10 mg q6h) for symptomatic relief, and [[mannitol]] and [[acetazolamide]] to reduce the elevated intracranial pressure. Antiepileptic therapy should be administered only if patients develop seizures. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 19:44, 6 October 2015
|
Cavernous sinus thrombosis Microchapters |
|
Differentiating Cavernous sinus thrombosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cavernous sinus thrombosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Cavernous sinus thrombosis medical therapy |
|
Risk calculators and risk factors for Cavernous sinus thrombosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cavernous sinus thrombosis is a medical emergency. Pharmacologic medical therapies for cavernous sinus thrombosis include antithombotic agents, antibiotics, and drugs such as mannitol, steroids and acetazolamide to decrease the intracranial pressure. Empiric antimicrobial therapy for septic thrombosis of cavernous or dural venous sinus includes metronidazole plus either nafcillin or oxacillin with either ceftriaxone or cefotaxime. Generally, the preferred empiric regimen for the treatment of cavernous sinus thrombosis is (Vancomycin 30–45 mg/kg IV q8–12h for 3-4 weeks OR Nafcillin 2 g IV q4h for 3-4 weeks OR Oxacillin 2 g IV q4h for 3-4 weeks) AND (Ceftriaxone 2 g IV q12h for 3-4 weeks OR Cefotaxime 8–12 g/day IV q4–6h for 3-4 weeks) AND Metronidazole 7.5 mg/kg IV q6h for 3-4 weeks. If the risk of MRSA is high, vancomycin should be used instead of either nafcillin or oxacillin. Other pharmacologic therapies include antithrombotic agents (usually LMWH) to prevent clot formation, steroid therapy (e.g. Dexamethasone 10 mg q6h) for symptomatic relief, and mannitol and acetazolamide to reduce the elevated intracranial pressure. Antiepileptic therapy should be administered only if patients develop seizures.
Medical Therapy
- Antithrombotics to prevent clot formation
- Note: Antithrombotics may be contraindicated. Cerebral infarction and intracranial hemorrhage must first be ruled out by head CT scan prior to administration of antithrombotic agents
- Antieleptics – as indicated
- Antibiotics – if infectious precipitant
- Reduction of intracranial pressure
- Medical: mannitol, steroids, acetazolamide, repeat LPs
- Shunt
Antimicrobial Regimen
- Cavernous sinus thrombosis is considered a medical emergency.
- Duration of therapy is usually a total of 3-4 weeks. More prolonged administration of antimicrobial therapy (total of 6-8 weeks) may be indicated among patients who are suspected to have developed complications (e.g. suppurative intracranial disease).
- ENT surgery must be consulted to evaluate the need of surgical drainage (e.g. sphenoidotomy if sphenoid sinus infection is the primary cause).
- Septic thrombosis of cavernous or dural venous sinus
-
- Preferred regimen: (Vancomycin 30–45 mg/kg IV q8–12h for 3-4 weeks OR Nafcillin 2 g IV q4h for 3-4 weeks OR Oxacillin 2 g IV q4h for 3-4 weeks) AND (Ceftriaxone 2 g IV q12h for 3-4 weeks OR Cefotaxime 8–12 g/day IV q4–6h for 3-4 weeks) AND Metronidazole 7.5 mg/kg IV q6h 3-4 weeks
- Note (1): If risk of MRSA is high, Vancomycin should be administered instead of either nafcillin or oxacillin
- Note (2): The optimal duration of therapy remains unclear
- 2. Specific anatomic considerations
- 2.1 Cavernous sinus
- Preferred regimen: Vancomycin 30–45 mg/kg IV q8–12h for 3-4 weeks AND (Ceftriaxone 2 g IV q12h for 3-4 weeks OR Cefotaxime 8–12 g/day IV q4–6h for 3-4 weeks) AND Metronidazole 7.5 mg/kg IV q6h for 3-4 weeks
- Note: Daptomycin 8–12 mg/kg IV q24h OR Linezolid 600 mg IV q12h could be considered for patients unable to tolerate vancomycin
- 2.2 Lateral sinus
- Preferred regimen: Cefepime 2 g IV q8h for 3-4 weeks AND Metronidazole 500 mg IV q8h for 3-4 weeks AND Vancomycin 15-20 IV mg/kg for 3-4 weeks
- Alternative regimen: Meropenem 1-2 g IV q8h 3-4 weeks AND Linezolid 600 mg IV q12h 3-4 weeks
- 2.3 Superior sagittal sinus
- Preferred regimen: Ceftriaxone 2 g IV q12h for 3-4 weeks AND Vancomycin 15–20 mg/kg for 3-4 weeks AND Dexamethasone 10 mg IV q6h continued until symptomatic improvement and tailed gradually over several weeks
- Alternative regimen: Meropenem 1–2 g IV q8h for 3-4 weeks AND Vancomycin 15–20 mg/kg for 3-4 weeks AND Dexamethasone 10 mg IV q6h continued until symptomatic improvement and tailed gradually over several weeks
- 3. Pathogen-directed antimicrobial therapy
- Staphylococcus aureus, methicillin-resistant (MRSA)[5]
- Preferred regimen: Vancomycin 15–20 mg/kg/dose IV q8–12h for 4–6 weeks
- Alternative regimen: Linezolid 600 mg PO/IV q12h for 4–6 weeks OR TMP-SMX 5 mg/kg/dose PO/IV q8–12h for 4–6 weeks
- Pediatric dose: Vancomycin 15 mg/kg/dose IV q6h 4–6 weeks OR Linezolid 10 mg/kg/dose PO/IV q8h 4–6 weeks
- Note (1): Surgical evaluation for incision and drainage of contiguous sites of infection or abscess is recommended whenever possible
- Note (2): Consider the addition of Rifampin 600 mg qd or 300–450 mg bid to vancomycin
References
- ↑ Saposnik, Gustavo; Barinagarrementeria, Fernando; Brown, Robert D.; Bushnell, Cheryl D.; Cucchiara, Brett; Cushman, Mary; deVeber, Gabrielle; Ferro, Jose M.; Tsai, Fong Y.; American Heart Association Stroke Council and the Council on Epidemiology and Prevention (2011-04). "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association". Stroke; a Journal of Cerebral Circulation. 42 (4): 1158–1192. doi:10.1161/STR.0b013e31820a8364. ISSN 1524-4628. PMID 21293023. Check date values in:
|date=(help) - ↑ Ebright, J. R.; Pace, M. T.; Niazi, A. F. (2001-12-10). "Septic thrombosis of the cavernous sinuses". Archives of Internal Medicine. 161 (22): 2671–2676. ISSN 0003-9926. PMID 11732931.
- ↑ Singh, B. (1993-09). "The management of lateral sinus thrombosis". The Journal of Laryngology and Otology. 107 (9): 803–808. ISSN 0022-2151. PMID 8228594. Check date values in:
|date=(help) - ↑ Southwick, F. S.; Richardson, E. P.; Swartz, M. N. (1986-03). "Septic thrombosis of the dural venous sinuses". Medicine. 65 (2): 82–106. ISSN 0025-7974. PMID 3512953. Check date values in:
|date=(help) - ↑ Liu, Catherine; Bayer, Arnold; Cosgrove, Sara E.; Daum, Robert S.; Fridkin, Scott K.; Gorwitz, Rachel J.; Kaplan, Sheldon L.; Karchmer, Adolf W.; Levine, Donald P.; Murray, Barbara E.; J Rybak, Michael; Talan, David A.; Chambers, Henry F.; Infectious Diseases Society of America (2011-02-01). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (3): –18-55. doi:10.1093/cid/ciq146. ISSN 1537-6591. PMID 21208910.